SOAT1 and hepatocellular carcinoma: A number of pharmacological inhibitors can be used for the inhibition of the JAK/STAT signaling pathway in controlling HCC (Mansour et al., 2014; Poulou et al., 2015; Gao et al., 2015b; Duffy et al., 2017; Luo, 2017; Zhu et al., 2017; He et al., 2018; Hiraoka et al., 2019; Hin Tang et al., 2020; Pinter et al., 2021).